Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Personalized molecular reprogramming of the tumor immune microenvironment and engineered adoptive cell transfer in synergy with ion-beam radiotherapy for next-generation curative cancer treatments

Objective

Cancer is a complex multifaceted disease. To conquer cancer, a multidisciplinary approach for rational design of multimodal therapies is imperative. Ground-breaking discoveries in immunotherapy and precision radiotherapy (RT) coupled with initial encouraging results of their combined application, have engendered hope that curative cancer treatments may become possible. Our objective is to harness the full synergistic potential of both modalities through deeper comprehension of the tumor immune microenvironment (TIME) evolution in response to therapy selection pressures. We propose innovative strategies to overcome five major obstacles limiting immunotherapy success: i) tumor camouflage from immune cell recognition, ii) limited immune cell homing and tumor trafficking, iii) paucity of immune activating signals, iv) suppressive signals in the TIME, and v) failure to induce deep memory responses for durable antitumor immunity. The convergence of four research fields, each represented by pioneering scientists, provides a unique opportunity to revolutionize current cancer treatment. To reprogram TIME and create an immunopermissive tumor niche we will employ a broad spectrum of clinical-grade ion beams including protons, helium-, carbon-, and oxygen ions with unique biophysical properties. These novel beam qualities, combined with targeted molecular countermeasures against key tumor immune evasive mechanisms, such as interference with TGFbeta- and integrated stress response pathways, will establish an effective in situ cancer vaccination strategy. In synergy with RT-mediated TIME reprogramming, two adoptive immune cell therapies will be explored: personalized vaccine-induced T cells targeting tumor-specific intracellular neoantigens and chimeric antigen receptor (CAR) T cells engineered to specifically recognize tumor membrane-associated antigens. Our team is uniquely positioned worldwide to develop the next generation of precision immunoradiotherapy.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-SYG - HORIZON ERC Synergy Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-SyG

See all projects funded under this call

Host institution

UNIVERSITATSKLINIKUM HEIDELBERG
Net EU contribution
€ 4 325 147,75
Address
IM NEUENHEIMER FELD 672
69120 HEIDELBERG
Germany
Region
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 4 325 147,75

Beneficiaries (4)